The Mexican Federal Commission for the Protection against Sanitary Risk (Cofepris) has given the approval for the Covid-19 vaccine emergency use authorization, developed by Pfizer-BioNTech, according to a statement given on Saturday by Deputy Health Minister, Hugo Lopez Gatell.
At a press conference, broadcast on Twitter, Gatell stated, “Cofepris gave an emergency use authorization to the Pfizer-BioNTech vaccine against the SARS-CoV-2 virus to prevent the spread of COVID-19.”
According to the revelation by Mexican health officials, presently, Mexico is the fourth country, who has taken the step of authorizing Pfizer-BioNTech Covid-19 vaccine for emergency use.
For Mexico, the first 250,000 doses of the authorized Covid-19 vaccine will be arriving by December end be administered to health and medical workers. Further, 2 million additional doses will be circulated throughout January and February. The monthly supply of the vaccine will be extended to 1 2 million as anticipated from the beginning of March.
Though, given emergency usage approval, Pfizer-BioNTech’s vaccine comes with a logistical disadvantage which is the condition of having -70 degrees Celsius temperature for storage and transportation. Moreover, the developers have given a prior commitment for delivering the vaccine on their own to the Mexican certified vaccination centers.
Bengaluru: Transport department employees in Karnataka have called for a statewide strike starting December 31,… Read More
New Traffic Rules on Bengaluru-Mysuru ExpresswayIn light of the Kannada Sahitya Sammelana taking place in… Read More
Brisbane, Gabba Stadium: The third match of the five-match Test series between India and Australia… Read More
The development was revealed by the Radiological Medical Research Center's General Director during a Russian… Read More
Bengaluru: The South Western Railway (SWR) has announced that train services between Bengaluru and Mysuru… Read More
New Delhi: The "One Nation, One Election" bill, which aims to allow simultaneous Lok Sabha… Read More
This website uses cookies.
Leave a Comment